CEL-SCI announces proposed public offering of common stock

CEL-SCI Corporation (NYSE American: CVM) announced plans for a public offering of common stock and pre-funded warrants, according to a company statement. The clinical-stage cancer immunotherapy company said the offering will be conducted on a best-efforts basis.

The Vienna, Virginia-based company stated it intends to use proceeds to fund continued development of its investigational therapy Multikine, support general corporate purposes, and provide working capital. ThinkEquity will serve as the sole placement agent for the transaction.

CEL-SCI noted the offering remains subject to market conditions, with no assurance regarding completion timing, size, or final terms. The securities will be offered under a shelf registration statement filed with the Securities and Exchange Commission on July 3, 2025, and declared effective on August 12, 2025.

The company's Multikine therapy has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. The treatment has been administered to more than 740 patients in clinical studies.

CEL-SCI operates facilities in Vienna, Virginia, and the Baltimore, Maryland area. The company focuses on developing immunotherapy treatments designed to boost patients' immune systems before conventional cancer treatments.

You May Also Be Interested In

• Kazia Therapeutics launches public offering of ADS and warrants
• MBX Biosciences doses first patient in Phase 3 hypoparathyroidism trial
• Southern Cross Acquisition II closes $76.5M IPO on Nasdaq